Skip to main content
Skip to footer

Akari Therapeutics

A Revolution in Treating Autoinflammatory & Orphan Diseases

HOME
ABOUT
- Close
- COMPANY OVERVIEW
- MANAGEMENT
- BOARD OF DIRECTORS
AREAS OF FOCUS
INVESTOR RELATIONS
PRESS
- Close
- PRESS RELEASES
- STORIES
CONTACT US

Main Content

Slide

ADVANCED THERAPIES

FOR AUTOIMMUNE &

INFLAMMATORY DISEASES

NOTICE & RESULTS OF GENERAL MEETING ON NOVEMBER 7, 2024 NOTICE & RESULTS OF
GENERAL MEETING ON
NOVEMBER 7, 2024

RECENT PRESS RELEASES

Akari Therapeutics Regains Full Nasdaq Compliance

November 19, 2024

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

November 14, 2024

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio Inc. Merger

November 8, 2024

Akari Therapeutics Announces Effectiveness of Form S-4 and General Meeting Date of November 7, 2024 Related to Peak Bio Merger

October 15, 2024

Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics

September 18, 2024

Footer

Follow Us

Privacy Statement

Expanded Access

Copyright © 2024 · Akari Therapeutics · Site Designed by Polus Digital, Inc.